Cryopreservation critical process parameters: Impact on post-thaw recovery of cellular product by Abazari, Alireza et al.
Poster Number 46 
CRYOPRESERVATION CRITICAL PROCESS PARAMETERS: IMPACT ON POST-THAW RECOVERY OF 
CELLULAR PRODUCT 
 
Alireza Abazari, PhD, BioLife Solutions, Inc. 
aabazari@biolifesolutions.com 
Brian J Hawkins, PhD, BioLife Solutions, and University of Washington Faculty of Medicine, Anesthesiology and 
Pain Medicine 
Aby J Mathew, PhD, BioLife Solutions, Inc. 
 
 
Key Words: Cryopreservation, Critical Process Parameters  
 
Technological advances have transformed cells from mere drug targets into potent ‘living drugs’ with the 
potential to cure formerly incurable diseases such as cancer. Such Regenerative Medicine Advanced Therapies 
(RMATs) require stringent and complex vein-to-vein support to deliver their intended function. Cold Chain 
pertains to strategies designed to ensure the product potency and efficacy during ex-vivo transition, and 
includes various components starting from the source material collection, to culture and expansion process, 
formulation, fill-finish and packaging, storage, transportation, chain of custody, and delivery. Biopreservation is 
the overarching theme of the cold chain and refers to strategies to slow down or fully suspend the biological 
clock to allow logistical considerations. The two main modes of biopreservation are hypothermic storage and 
cryopreservation. This presentation aims to map the connection between a specific biopreservation strategy, 
namely cryopreservation, and formulation and fill-finish, and how implementation of Biopreservation Best 
Practices can improve the outcome of Cold Chain.  
 
There is more to Biopreservation than storage on ice or freezing at a rate of -1°C/min in 10% DMSO. To 
comprehend the rationale behind Biopreservation Best Practices, a basic understanding of cellular response to 
cold and freezing is essential. In this study, we highlight critical process parameters (CPPs) of cryopreservation, 
such as freezing and thawing rates, storage and post-thaw stability, and container type, among others. Using a 
Jurkat T-cell model, we will discuss the impact of these CPPs on critical quality attributes (CQAs) such as 
viability, yield, proliferation rate, and return to function. We will also discuss the connection between variability in 
CPPs and characterization assay results. In general, implementation of best practices in formulation can directly 
address multiple process bottlenecks, including GMP compliance, minimizing freezing damage, support stability 
during storage and against transient warming events, support post-thaw stability, and excipient use. The CQAs 
may also be significantly improved by adjusting a few parameters in the freezing profile. For example, a missed 
or improper nucleation step during freezing may result in decreased recovery and increased variability in post-
thaw proliferation rates. We have also found that the feeding timeline prior to freezing can have a profound 
impact on post-thaw viability and recovery in Jurkat T cells. While discussing these results, we will also review 
the underlying biophysics of such phenomena. The basic knowledge of designing a freezing profile may 
introduce degrees of freedom to process engineers to minimize the DMSO concentration in the formulation, and 
improve the CQAs of “hard-to-freeze” cells such as Natural Killer (NK) cells. We will also discuss the interplay 
between the cryopreservation CPPs and the choice of container format and how it may impact the CQAs. 
 
Incorporation of Biopreservation Best Practices conveys 
important advantages upstream and downstream of cell 
manufacturing, including: (1) Assisting in the selection of the 
right delivery model, i.e. fresh vs. frozen, and the specific 
infrastructure and personnel requirements of each, based 
on which a commercial model is structured, (2) Reducing 
the Quality/Regulatory footprint of Cold Chain, and 
eliminating the burden of process changes when advancing 
to clinical trials, and (3)  Improving the product CQAs, all of 
which could potentially improve safety and efficacy of 
RMAT-based clinical trials. As such, early incorporation of 
Biopreservation Best Practices in cell manufacturing is 
highly recommended.  
 
 
Cryopreservation CPPs and their impact on post-
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